We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Eden Research Plc | LSE:EDEN | London | Ordinary Share | GB0001646941 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4.85 | 4.70 | 5.00 | 4.95 | 4.85 | 4.95 | 383,710 | 08:00:04 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 1.83M | -2.24M | -0.0042 | -11.55 | 25.87M |
Date | Subject | Author | Discuss |
---|---|---|---|
28/6/2019 11:51 | OPTIONS RNS "In respect of 2018: · To the CEO Sean Smith nil cost options over 1,688,889 ordinary shares. · To the CFO Alex Abrey nil cost options over 1,333,333 ordinary shares. The vesting date of the options is 30 June 2022, and they only become exercisable if the following share price performance conditions are met: 50% of the options become exercisable if the weighted average Ordinary Share price in the 45-day period ending on the vesting date is £0.25 or above. Between weighted average Ordinary Share prices of £0.25 and £0.375, vesting shall be pro-rata and on a straight-line basis between 50% and 100%. Below £0.25 the options are not exercisable and lapse in full." That is either not very stretching or a total gift given the current share options which have their ending date 30th September 2018. It absolutely seems like the latter to me. I'd rather they had more options, but at a much higher price! What is it with AIM and its total lack of guidance & morality around the issue of options, remuneration committee's and alike. It's appalling. | investingisatrickygame | |
28/6/2019 11:48 | Cheers guys..it's easy to forget how much potential the company has, something has to break soon. | 33mick | |
28/6/2019 11:27 | Life Expectancy Falters in the UK: Slow Death but Fast Profits for the Agrochemical Sector A special report in the Observer newspaper in the UK on 23 June 2019 asked the question: Why is life expectancy faltering? The piece noted that for the first time in 100 years, Britons are dying earlier. The UK now has the worst health trends in Western Europe. Aside from the figures for the elderly and the deprived, there has also been a worrying change in infant mortality rates. Since 2014, the rate has increased every year: the figure for 2017 is significantly higher than the one in 2014. To explain this increase in infant mortality, certain experts blame it on ‘austerity&rsq While all these explanations may be valid, according to environmental campaigner Dr Rosemary Mason, there is something the mainstream narrative is avoiding. She says: “We are being poisoned by weedkiller and other pesticides in our food and weedkiller sprayed indiscriminately on our communities. The media remain silent.” | supersonico | |
28/6/2019 11:02 | Commercial news about these will give it a nudge. Molluscicide news Insecticide news Wider Mevalone application label extensions TRIGEMOL / EUGETI / CAGENOLETA Post Harvest/ other Seipro products from Sumiagro/Sipcam Cedroz registrations/ Mevalone approval EGTOP Organic announcement Eugenol / Thymol / Geraniol Strategic update/strategic investor/ Bayer news TT news Bayer / TT parallel delay revelation.. Sustaine news from Sipcam and collaborators / Eastman Field crops trials Cotton/wheat/soybean / 'highly potent active agent encapsulated' news Anti-microbial news Xinova Any pipeline news SC Johnson Collaboration with DE SANGOSSE biocontrôle anti-mildiou PommeDeTerre. | supersonico | |
28/6/2019 10:37 | "what's next to look forward too" Well if we had that reliable information we wouldn't be sat at a paltry 11.5p Whether you look forward to the following, who knows. 1) The Chairman originally said he would buy double what he has, so maybe further purchases to come, in short order :) 2) TT zzzzzzz 3) Bayer zzzzzzz 4) Sipcam evaluation of Sustaine and a commercial arrangement around the same I wouldn't look to far beyond that to be honest in terms of 'short order' A bit of support from our brokers and PR firm wouldn't go a miss. A bit more bullishness from our Company, within the realms of fair value wouldn't go a miss either. It seems to me that Eden's shares are suffering from long-term MDD :) "Major depressive disorder (MDD), also known simply as depression, is a mental disorder characterized by at least two weeks of low mood that is present across most situations. It is often accompanied by low self-esteem, loss of interest in normally enjoyable activities, low energy, and pain without a clear cause. People may also occasionally have false beliefs or see or hear things that others cannot" | investingisatrickygame | |
28/6/2019 10:12 | well that Buy was a long time coming, Cheer me up and remind me guys what's next to look forward too On the short order menu of news! I'm hanging in there...Every share has its Day...In the Sun..ours is well overdue | 33mick | |
28/6/2019 09:59 | Finally.... | bjlk | |
28/6/2019 09:43 | 11.5p, we'll soon be getting a nose bleed :) | investingisatrickygame | |
28/6/2019 08:13 | 27-Jun-19 Buy Lykele van der Broek 10.5 GBX 40,000 180000 27-Jun-19 Buy Lykele van der Broek 10.47 GBX 40,000 180000 27-Jun-19 Buy Lykele van der Broek 10.75 GBX 40,000 180000 27-Jun-19 Buy Lykele van der Broek 10.74 GBX 100,000 180000 27-Jun-19 Buy Lykele van der Broek 11.41 GBX 138,500 358500 | supersonico | |
28/6/2019 07:52 | Hope so. Quite reassuring to see a 7% move on a purchase of only 35 grand or so. He's obviously had so many people ask him when he's buying shares he eventually caved in. | dplewis1 | |
28/6/2019 07:29 | At last. First purchase of two? | brucie5 | |
28/6/2019 07:13 | Is Michael Walters still around? | purplepelmets | |
28/6/2019 07:10 | Nice buy from Short Order Lykele. | supersonico | |
28/6/2019 07:04 | Finally.. Lykele has bought some shares!! | dplewis1 | |
27/6/2019 18:44 | Always fun to observe the purest of pure serendipity of unrelated Eden investors. | supersonico | |
27/6/2019 16:50 | 113,500 Buy at 11.50p,will we get RNS tomorrow? | monet | |
27/6/2019 13:04 | Mrs $$New York :) wan 31 Jul '19 - 07:37 - 564 of 564 0 0 0 Brucie...I agree that the initial market for Mevalone appears small in comparison. However, Sipcam's exclusivity for Mevalone would suggest they are expecting to address a much larger market going forwards. In this regard, I would imagine they are, at the very least, as 'proactive' as Sumi-Agro in this regard. In my opinion it is instructive, in terms of the efficacy of Eden's products, product withdrawals, user/consumer backdrop and indeed the regulatory backdrop, that Eden has now been granted three emergency use authorisations....an | supersonico | |
27/6/2019 12:04 | Looks like Mrs 51k is back buying | northwick | |
27/6/2019 09:28 | More trades than posts on the bb today, things are looking up! | dplewis1 | |
27/6/2019 08:33 | Oh dear, I hope they don't start thinking that they are the master race and invade Poland. | weyweyumfozo | |
25/6/2019 18:29 | Eden Research @edenresearch Eden Research plc Retweeted The Biopesticide Summit 2019 Felicity Lenyk will be presenting on Eden's #Sustaine encapsulation technology at the @biosummit19 on the 2-3rd July in Swansea. Felicity Lenyk from @edenresearch and Majda Ortan from #PHAgrohom adding to our line up, both very inspiring women! | supersonico | |
25/6/2019 18:09 | BBC Radio 4 today Among others, plastic and shampoo | investingisatrickygame | |
25/6/2019 15:55 | Grateful to Super for putting me onto this guy. This video of a lecture in Germany is of material interest to what EDEN provide, including, 16 minutes in, a mention of the risk posed by canine flea treatments. 3/4 of the world's bees have neonicotinoids in their foods. | brucie5 | |
25/6/2019 15:40 | I wonder if EDEN should give these guys a call. | brucie5 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions